HCH6-1

Research use only, not for human use.

HCH6-1 is a competitive Formyl peptide receptor 1 (FPR1) antagonist.

HCH6-1 is a competitive Formyl peptide receptor 1 (FPR1) antagonist.

In a cell-impermeable cytochrome c reduction assay, HCH6-1 significantly inhibits superoxide anion generation in fMLF (FPR1 agonist)-activated neutrophils with anIC50 of 0.32 μM. HCH6-1 has fewer inhibitory effects in WKYMVm (dual FPR1/FPR2 agonist)- and MMK1 (FPR2 agonist)-activated neutrophils, with IC50s of 4.98±0.27 μM and 17.68±2.77 μM, respectively.HCH6-1 does not induce LDH release even at 30 μM, so it does not have cytotoxic effects in human neutrophils. HCH6-1 does not alter the level of xanthine/xanthine oxidase superoxide anion and DPPH radical in cell-free systems.HCH6-1 significantly inhibits elastase release in fMLF-activated neutrophils, with an IC50 of 0.57 μM. However, in neutrophils triggered by WKYMVm or MMK1, HCH6-1 inhibits elastase release at higher concentrations, with IC50s of 5.22±0.69 μM and 10.00±0.65 μM, respectively.

HCH6-1 (intraperitoneal injection; 50 mg/kg; 1 h before LPS spray or 30 min after LPS spray) alone does not induce airspace inflammation. HCH6-1 pretreatment reduces inflammatory cell infiltration and distortion of pulmonary architecture in the presence of LPS. HCH6-1 posttreatment shows inhibitory effects on neutrophil accumulation and lung damage in LPS-induced ALI mice. Animal Model:C57BL/6 mice (20-25 g, 7-8 weeks old)Dosage:50 mg/kg Administration:Intraperitoneal injection; 50 mg/kg; 1 h before LPS spray or 30 min after LPS spray Result:Ameliorated ALI in LPS-induced mice.HCH6-1-mediated decreasing of neutrophil recruitment serves as a protective mechanism in ALI mice.

——

Others

Other Targets

formyl peptide receptor (FPR)

——

——

1435265-06-7

469.53

C28H27N3O4

>98% (HPLC)

DMSO:250 mg/mL (532.45 mM; Need ultrasonic)

COC(=O)[C@@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)c1ccccc1

——

(-20℃)

With Ice Pack

≥ 2 years